Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Key Highlights
- ➤Oncodetect WGS sensitivity reached 72.2%, versus 42.2% for WES after surgery
- ➤WGS detected ctDNA in 15 additional patients missed by WES, all below 20 ppm
- ➤Detectable post-surgical ctDNA indicated 10.6-fold higher recurrence risk
- ➤Two-year disease-free survival was 36.2% with ctDNA versus 92.3% without
- ➤Stage II ctDNA-positive patients faced approximately 31-fold higher recurrence risk
Expert Statements
Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East and principal investigator of the Beta-CORRECT study
“Beta-CORRECT adds important clinical evidence supporting the prognostic value of highly sensitive MRD testing in colorectal cancer. The ability to identify additional patients with detectable ctDNA after surgery may help refine recurrence risk assessment beyond traditional clinical factors. Continued research will help determine how these findings can best inform patient management.”
Rick Baehner, Divisional vice president, chief medical officer, precision oncology, Abbott's cancer diagnostics business
“These findings reinforce why sensitivity matters in MRD testing, particularly after surgery when ctDNA can be difficult to detect. By identifying additional patients with residual disease, we can provide physicians with important molecular information about recurrence risk at a critical point in care.”
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer PR Newswire
* Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing(1) * Building on its leadership in colorectal cancer screening with the Cologuard(®) test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring ABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain. Abbott (NYSE: ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect(®) molecular residual disease (MRD) test achieved a 30-percent absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery, compared with the whole-exome sequencing (WES) Oncodetect test, using a single post-surgery blood draw.(1)
Get started
Create a free account to read the full story.